Impaired growth after TBI prior to BMT has been a constant finding in children with leukemia. The growth of poor-risk neuroblastoma (NBL) survivors treated with myeloablative preparative regimens and ABMT at the Hospital for Children and Adolescents, University of Helsinki, since 1982 is reported. Two separate groups were analyzed: (1) The TBI − patients (n = 15) were conditioned with high-dose chemotherapy only. They had been treated at the age of 1.0-6.3 (mean 3.0) years and the post-ABMT follow-up time was 1.5-14.5 (mean 7.7) years. (2) The TBI + patients (n = 16) had received TBI in addition to high-dose chemotherapy. They had been treated at the age of 1.3-4.8 (mean 3.0) years, and the post-ABMT follow-up time was 1.5-8.0 (mean 4.7) years. The height standard deviation score (SDS) was similar for the two groups at the time of diagnosis, −0.3 ± 1.2 (mean ± s.d.), and at the time of ABMT, −0.7 ± 1.1. After transplantation, the height SDS continued to decrease in the TBI + group, the mean being −2.0 SDS at 5 years after ABMT. In the TBI − group, the mean height SDS remained within −0.7 to −0.9 to the 10 years of follow-up. Five patients received growth hormone (GH) therapy starting 2-6 years after ABMT. They all had low GH secretion in provocative tests. All showed some response to GH therapy. The mean height SDS increased 0.4 SDS during the 3 years following the start of GH therapy, while in the untreated patients a decrease of 0.8 SDS during the corresponding time (P = 0.009) was observed. We conclude that NBL patients grow poorly following ABMT when TBI is included in the conditioning regimen, but close to normally when treated without TBI. The need for GH therapy should be evaluated early to avoid an unnecessary decrease in final height.
many studies. [1] [2] [3] [4] [5] [6] [7] Usually the impaired growth, as indicated by decrease in growth velocity or in height standard deviation score (SDS), has been shown to continue for several years to a variable extent. Type (single vs fractionated) and dose of TBI and possibly previous central nervous system irradiation have been factors affecting the outcome. Most of these studies concern children with leukemia or aplastic anemia. Neuroblastoma (NBL) is the most common extracranial solid tumor of childhood, and poor-risk NBL remains today a real therapeutic challenge. High-dose chemotherapy and autologous BMT (ABMT) have been used in the treatment of NBL patients from the late 1970s. These patients differ from leukemia patients in many respects: they are usually younger, they do not receive additional central nervous system irradiation except to local bony metastases, their conventional chemotherapy contains drugs unusual in the treatment of leukemia, such as cisplatin, and their preparative regimen for BMT is different and it may or may not contain TBI. Further, at transplantation, autologous rather than allogeneic stem cells are most often used and, accordingly, graft-versus-host disease (GVHD) and corticosteroid therapy play no role in NBL. There are very few reports on post-transplant growth of children with NBL conditioned with TBI, and even less on those without TBI. The growth velocity of NBL patients with TBI has been observed to be less than that of leukemia patients. 8 At the Hospital for Children and Adolescents, University of Helsinki, patients with poor-risk NBL have been treated with high-dose chemotherapy and ABMT since 1982. Before 1987 they did not receive TBI, while it has been part of the preparative regimen in most patients since that time. We analyzed long-term post-transplant growth of NBL survivors treated with and without TBI. Five patients have received growth hormone (GH) therapy for 2-5 years. We also report the response to GH in these patients.
Patients and methods
This study includes all patients with poor-risk NBL (stage IV disease or stage III disease with N-myc amplification) who have been treated at the Hospital for Children and Adolescents, University of Helsinki, with myeloablative preparative therapy and ABMT since 1982 and who have survived relapse-free for at least 1 year post-transplant. The patients comprise all long-term survivors of poor-risk NBL in Finland during the time period. They were both diag- nosed and treated at this hospital (n = 25) or they were referred to this center for evaluation for high-dose therapy and ABMT (n = 6). The post-ABMT follow-up of five patients took place in the referring hospitals; the others were mainly followed up at this hospital.
Treatment protocols
Between 1982 and 1986 the conventional chemotherapy for poor-risk NBL patients was etoposide and cisplatin only. Surgery was performed early and usually repeated one to two times. Local irradiation was rarely used. The preparative treatment for ABMT consisted of high-dose melphalan (140-180 mg/m 2 , single dose) only. 9 These patients are included in the TBI − group of this study.
In 1987 a new treatment protocol was introduced. 10 All patients received conventional multiagent chemotherapy including cyclophosphamide, dacarbazine, vincristine, cisplatin, doxorubicin and etoposide. Surgery was frequently performed late. Local irradiaton of 15-20 Gy was delivered to the tumor bed if tumor was left behind at surgery, and to bulky bony metastases. The preparative regimen for ABMT consisted of high-dose chemotherapy (VMP) using etoposide (total dose 300 mg/m 2 ), melphalan (total dose 210 mg/m 2 ) and cisplatin (90 mg/m 2 ), and TBI of 10 or 12 Gy given in five to six fractions over 3 days. Two patients with recurrent metastatic retinoblastoma (RBL) were treated identically to the NBL patients. All these patients are included in the TBI + group of this study. During the later time period, two patients with poor-risk, stage III NBL were treated as the other poor-risk NBL patients, but they were conditioned for ABMT with chemotherapy including etoposide (total dose 750 mg/m 2 ), carboplatin (total dose 1500 mg/m 2 ) and thiotepa (total dose 900 mg/m 2 ). Full tumor dose radiotherapy was administered to the field of bulky primaries, but no TBI was given. These patients are included in the TBI − group of this study.
TBI − patients
Fifteen children (9 boys, 6 girls) had high-dose chemotherapy without TBI prior to ABMT at ages 1.0 to 6.3 (mean 3.0) years (Table 1) . Poor-risk NBL was diagnosed at 0.1-5.7 (mean 2.3) years. With two exceptions, patients in this group were treated between 1982 and 1986 and the post-ABMT follow-up was 1.5 to 14.5 (mean 7.7) years. The age of the patients at the time of this study was 3.9 to 16.1 (mean 10.2) years. Local irradiation of 4-24 Gy to the tumor bed or metastases was delivered in six patients. None had irradiation to the skull area.
TBI + patients
Sixteen children (9 boys, 7 girls) received VMP+TBI prior to ABMT at ages between 1.3 and 4.8 (mean 3.0) years (Table 1) . Malignancy (NBL = 14, RBL = 2) had been diagnosed at 1-3.9 (mean 2.5) years. The post-ABMT followup was 1.5-8.0 (mean 4.7) years. The age of the patients at the time of this study was 4.3 to 12.8 (mean 6.4) years. Local irradiation prior to ABMT was delivered in 10 patients, 5 to the area of cranium in doses of 6, 20, 20, 32 and 46 Gy, and 7 to the tumor bed in doses of 15-20 Gy. The dose of TBI was 10 Gy in 11 patients and 12 Gy in 5 patients.
Post-transplant follow-up
All patients had repeat post-transplant evaluations at 1 to 2 month intervals during the first year. The interval increased during the subsequent years but they continued to be seen at least once a year. Patients underwent physical examination and appropriate testing for detection of recurrent disease. Patients with medical problems were treated accordingly. Heights were carefully measured at each check-up by an experienced nurse using a wall-mounted stadiometer.
Relative heights in SDS were estimated from national Finnish growth charts. 11 Thyroid function of the irradiated patients was assessed at 1 to 2 yearly intervals by measuring serum thyroid stimulating hormone and thyroxine levels. GH secretion was evaluated, when clinically indicated, by using insulin-arginine provocative tests. Four patients with height SDS below −2 and one with a decrease of height SDS of 1.6 were considered GH-deficient because their maximal GH responses to both stimuli were Ͻ10 g/l. They had received GH therapy for 2-5 years starting 2-6 years after ABMT (Table 2) .
Statistical methods
The significance of differences between the groups was calculated by the paired or unpaired two-tailed t-test or by Table 2 The growth (cm/year) and height SDS of GH treated patients before GH, at GH start, and during ongoing GH replacement analyses of variance with repeated measures. The correlations between age at transplant and growth was evaluated by multiple regression analyses.
Results
The mean height SDS of the patients treated with TBI decreased continuously over several years after ABMT, whereas the mean height SDS of the patients treated without TBI showed neither decrease nor catch-up after ABMT (Figure 1 ).
Growth before ABMT
At diagnosis, the height SDS (mean ± s.d.) for all patients was −0.3 ± 1.2 and the two groups, TBI + and TBI − , were similar. At the time of ABMT, the height SDS had decreased to −0.7 ± 1.1 (P = 0.004), again with no difference between the groups (Figure 1 ).
Growth after ABMT
After transplantation, the height SDS continued to decrease in patients in the TBI + group (Figure 1 ). Their mean height SDS decreased during the first year after ABMT from −0.6 to −1. and further to −2.0 at 5 years after ABMT. The decrease was statistically significant between the following time points: ABMT-1 year (P = 0.005), 1-2 years (P = 0.03), 2-3 years (P = 0.011), and 3-4 years (P = 0.034); patients on growth hormone therapy are excluded. In the TBI − group, the mean height SDS remained within −0.7 to −0.9 to the 10 years of follow-up. The height SDS in the TBI − group was significantly higher than in the TBI + group at 5 and 6 years after ABMT (Figure 1) .
Effect of TBI dose
During the first 2 years after ABMT, the height SDS of the patients with 12 Gy of TBI decreased 1.0 SDS, compared to 0.6 SDS in those with 10 Gy (NS). Of the patients followed over 2 years after ABMT, all four who had received 12 Gy, but 1/9 10 Gy, subsequently received GH therapy.
Neither age at ABMT nor sex correlated with decrease in height SDS.
The patients on GH therapy
Five patients received GH therapy starting 2-6 years after ABMT (Table 2) . Their age was 2.3 to 4.8 years at ABMT and 4.3 to 10.5 years when GH therapy was started. Patient 16 had retinoblastoma and had received local radiotherapy of 32 Gy to the left orbit and mandibular angle. No other patient had any extra radiotherapy in addition to TBI. Patient 23 had severe renal insufficiency after ABMT due to a fungal infection in his remaining kidney. Extirpation of his abdominal neuroblastoma had included nephrectomy. The remaining kidney was subsequently removed 1 year after ABMT and he received peritoneal dialysis until a kidney transplant 2.3 years after ABMT, 3 months after starting GH therapy ( Figure 2 ). All these five patients had biochemical evidence of GH deficiency tested with the insulin-arginine provocative test where their maximal GH peak was Ͻ10 g/l. Their pretreatment growth velocity was 3.0-4.1 cm/year. They received recombinant hGH at a dose of 0.1 IU/kg/day. During the first GH year, all showed a modest response to GH therapy with a mean growth of 6.6 cm. The response, however, decreased with prolonged treatment. During the fourth GH year the mean growth was only 4.7 cm (Table 2, Figure 2 ). During the first 3 GH years, the mean height SDS of the patients increased 0.4 SDS while it simultaneously decreased 0.8 SDS in the nonsubstituted patients in the TBI + group (P = 0.009). During the fifth year of GH therapy, the growth velocity was no better than before GH. All five patients were also receiving thyroxine replacement because of subclinical hypothyroidism.
Discussion
Our results indicate that the growth of poor-risk NBL patients, who had received a TBI containing preparative regimen prior to ABMT, was subnormal several years following transplantation. No patient demonstrated spontaneous catch-up growth during the follow-up period. In contrast, the growth of the TBI − patients was not impaired following ABMT.
Age and height SDS of the two patient groups did not differ at the time of diagnosis or at ABMT justifying the assumption that the patient groups were comparable even though the patients were mainly treated in different time periods and the conventional chemotherapy was different. The loss of height SDS during therapy before ABMT was similar and the mean height SDS of the total group was −0.7 at ABMT.
The growth of children with leukemia or aplastic anemia has been shown to be normal or only slightly impaired following BMT when chemotherapy only has been included in the conditioning regimen. 5, 12 We could not find corresponding information on children with NBL who are usually younger during therapy and have conventional chemotherapy different from that of the hematology patients. In this study with several years of follow-up, the mean height SDS of the TBI − patients decreased 0.4 SDS before and 0.3 SDS following ABMT. The growth of the two children treated after 1987 with more intensive chemotherapy was comparable but their follow-up time is still short. Our findings support the data of close to normal growth of children treated with cytostatic chemotherapy even when very high doses with ABMT support have been used.
The growth of children with leukemia and aplastic anemia treated with TBI has been shown to be impaired for several years following BMT especially if the patients have received previous central nervous system irradiation. 1, 2, [5] [6] [7] [13] [14] [15] In a 6-year follow-up study of 32 long-term survivors of cancer, all treated with TBI and BMT, Willi et al 8 observed that the 11 patients with NBL continued to grow poorly, whereas a comparison group of 21 patients with leukemia had essentially normal growth 2 years after the procedure and even showed some catch-up growth in years 4 to 6. Our results on the growth of NBL patients treated with TBI are in accordance with their study. According to our preliminary report on patients treated with TBI and BMT, the growth of NBL patients was more impaired than that of leukemia patients. 4 However, after a longer follow-up and a larger group of NBL patients, the difference between NBL and leukemia patients is no longer significant. No catch-up growth is seen in either group (Figure 3) . Several reasons for the poor growth after TBI and BMT have been proposed. A significant incidence of GH deficiency in leukemia patients treated with TBI has been reported. 1, 6, 7, 15, [17] [18] [19] Olshan et al 20 studied GH secretion of six transplanted NBL patients and showed GH deficiency in three patients; only one child had completely normal GH secretion. However, the response to GH therapy in three GH-deficient NBL patients was poor, suggesting a state of relative GH resistance. The direct effects of irradiation on the epiphyses or other soft tissues have been proposed to be one reason for poor growth in GH-treated transplant patients. 17 The GH status of our patients was not systematically evaluated, but only when clinically indicated and start of GH therapy was considered. Five patients, all with GH deficiency based on subnormal responses in provocative tests, received GH therapy starting 2-6 years after ABMT. They all showed some response to GH therapy with increasing growth velocities. In three, some catch-up growth was shown which did not occur in any patient in the TBI + group not receiving GH. The modest response to GH therapy in our patients was in accordance with the finding of the previously reported NBL patients and clearly poorer than the growth response of GH deficient non-tumor patients. 20 Despite the suboptimal response, our results suggest that treating GH-deficient transplanted NBL patients with substitute hormone therapy might be useful in increasing the final height although this has not yet been reached. Investigation of GH status and start of therapy should not be unnecessarily delayed if the best possible growth result is to be obtained. This is especially important in short children whose height expectancy is low even without malignant disease.
TBI has been widely used in poor-risk NBL patients as part of the preparative regimen before ABMT. However, TBI may not be necessary in all patients, and is not used in all contemporary programs. The superiority of high-dose 
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Figure 3
Mean height SDS before and after ABMT in total body irradiated and non-irradiated NBL patients, as compared with children with ALL who received TBI preparative for allogeneic BMT 4 or with children with brain tumors who were treated in this same hospital and received cranial doses of 16-56 Gy. 16 chemotherapy with ABMT compared with conventional chemotherapy in the treatment of high-risk NBL patients was confirmed in a randomized Childrens Cancer Group study with a 3-year event-free survival of 34% in the ABMT group. The preparative regimen did not include TBI. 21 In three non-randomized trials using TBI along with high-dose chemotherapy as preparative therapy for ABMT, a disease-free survival (DFS) of 34-49% has been reported. [22] [23] [24] In our older series without TBI, a 2.8-year survival of 54% was reported, 9 and even if updated now, and the patients retrospectively staged to III (regional lymph node metastases only) excluded, the very-long-term survival of 36% is reached in this very small group of patients. In our later cohort including TBI we have published a 53% 4-year DFS post-transplant, 10 meaning today a 6-year DFS because no further relapses have occurred. We have advocated stratifying patients according to early response to therapy. Prompt 'in vivo purging' of bone marrow was a favorable prognostic factor resulting in 100% survival, and in these children TBI could probably be omitted.
In conclusion, our program for poor risk NBL including multi-agent chemotherapy and TBI peparative for ABMT results in good long-term survival figures (53% 6-year DFS) at the expense of impaired growth. This finding dictates: (1) search for equally effective regimens without TBI; (2) recognition of the problem, careful follow-up of patients, and early institution of GH replacement therapy in order to avoid unnecessary decrease of the final height.
